Stock Ratings / Health Care / XERS / options

TRVI (30) BRVE (46) ADRX (51) TRAX (44) ⌘ Pro Terminal →

Xeris Biopharma Holdings Inc. (XERS) Options Positioning, Max Pain & Unusual Sweeps

$10.75 +1.03% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.75

Xeris Biopharma Holdings Inc. (XERS) carries a Roarable Rating of C (Hold) with 64/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 64/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.1% avg 90D alpha vs SPY) →

ROARABLE C • HOLD / WATCH Cap $1.96B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on XERS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is XERS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Xeris Biopharma Holdings Inc. (NASDAQ: XERS) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 64/100 at a spot price of $10.75 (+1.03% 1D, market cap $1.96B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 11/20. Across 1016 tracked Health Care issuers, XERS ranks #138 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does XERS compare to TRVI and BRVE in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XERS carries a Roarable C (64/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 16.0%. By comparison, TRVI (Trevi Therapeutics Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -23.7%, cap $1.97B) and BRVE (Braveheart Bio Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC —, cap $1.91B). Among the 5-stock peer group, XERS leads on earnings multiple (N/A) while XERS leads on capital efficiency (16.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for XERS?

▼

Per XERS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001867096), Xeris Biopharma Holdings Inc. generated $291.8M in revenue (+43.7% YoY), $554.0K in net income, and $28.6M in free cash flow against $383.5M in total assets and $220.3M in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $10.75 (+0.00%)🧬 Disciplined Float (+0.24% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 9.8% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 64/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.1% avg 90D alpha vs SPY • 55.2% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE+2.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for XERS)Realized 20D OHLCV Swing Band: ±9.1%

Deterministic 5-Pillar Attribution (64/100 Composite)

🔍 WHY XERS SCORES 64/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 9.8% FCF Margin ($28.6M FCF) & 52% Gross Margin

▲ #2 Bullish Driver: Whale & Options Positioning+16/20 pts (25% of score)

20D Institutional Volume Accumulation (±9.1% realized swing band)

▼ #1 Drag / Risk Factor: Macro Regime Fit9/20 pts (-11 pt drag)

Macro rate sensitivity & RSI-14 (60.5) create a -11 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$10.46+4.7% Next Q

Q2 (-2Q)

Grade C$10.95-6.8% Next Q

Q3 (-1Q)

Grade C$10.21+5.3% Next Q

Current

Grade C$10.75+1.1% Hist 90D α

Trajectory: C (56) → C (64)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the XERS Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 64/100 (C) score, XERS faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($9.35) or 200D SMA ($7.52) invalidates the momentum regime and cuts Target Base ($11.04) toward Bear Floor ($8.61).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $XERS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “XERS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 64%NO 36%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±9.1%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (XERS)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for XERS.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating XERS & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on XERS
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

XERS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +69.56%▲ ASCENDING CHANNEL

2026-11-02O $10.64H $10.75L $10.64C $10.75VOL 1.75M

RES: $12.27SUP: $8.23SMA50: $9.35SMA200: $7.52

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

XERS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 XERS Butterfly Map → + Track XERS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

48.0%/yr Implied 5Y Growth

vs. +43.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on XERS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for XERS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for XERS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (XERS)

Health Care Rank #138 of 1016 ⚔️ TRVI vs XERS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (XERS vs. TRVI, BRVE, ADRX, TRAX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Xeris Biopharma Holdings Inc. (XERS) ranks #138 by composite RQD confidence (64/100, grade C) and #267 by equity capitalization ($1.96B). Within this direct 5-issuer industry benchmark cohort, XERS leads on earnings valuation at N/A trailing P/E, while XERS leads on capital efficiency and profitability with 16.0% ROIC and — gross margin. XERS currently leads its immediate peer cohort in composite quantitative strength at 64/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
XERS ACTIVE Xeris Biopharma Holdings Inc.	C	64/100	—	—	16.0%	+1.03%	$1.96B	Benchmark Subject
TRVI Trevi Therapeutics Inc.	E	30/100	—	—	-23.7%	+2.15%	$1.97B	/trvi-vs-xers →
BRVE Braveheart Bio Inc.	D	46/100	—	—	—	-2.62%	$1.91B	/brve-vs-xers →
ADRX ADARx Pharmaceuticals Inc.	D	51/100	—	—	—	-0.56%	$1.91B	/adrx-vs-xers →
TRAX First Tracks Biotherapeutics Inc.	D	44/100	—	—	-35.0%	-1.08%	$1.90B	/trax-vs-xers →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001867096

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Xeris Biopharma Holdings Inc. (XERS) reported GAAP revenue of $291.8M (+43.7% vs. FY2024 revenue of $203.1M , and +78.0% cumulative change since FY2023) , GAAP net income of $554.0K, operating cash flow of $28.6M, and free cash flow of $28.6M (+177.4% YoY). On the balance sheet, XERS closed FY2025 with $383.5M in total assets against $220.3M in total debt (Altman Z-Score: 2.11, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$291.8M	$554.0K	$28.6M	$28.6M	$383.5M	$220.3M
FY2024 (FY)	2024-12-31	$203.1M	-$54.8M	-$37.0M	-$37.0M	$323.1M	$217.0M
FY2023 (FY)	2023-12-31	$163.9M	-$62.3M	-$47.0M	-$47.0M	—	—

3. XERS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is XERS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does XERS compare to TRVI and BRVE in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for XERS?

Where is XERS trading relative to its 50-day, 200-day, and 52-week technical levels?

XERS last traded at $10.75 (+1.03% on volume of 1,745,572 shares), positioning the stock +14.97% above its 50-day simple moving average ($9.35) and +42.95% above its 200-day simple moving average ($7.52). Across its 52-week range of $5.25 to $11.42, XERS sits at the 89.1% percentile with a 14-day RSI of 60.5 (BULLISH MOMENTUM) and an implied next-earnings move of ±9.1% ($9.77 to $11.73).